About Zymeworks Inc.
Developing novel medicines for patients with difficult-to-treat cancers and other serious diseases.
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Vancouver, BC
- Founded
- 2003
- Company type
- Public Company
Zymeworks is a global biotechnology company developing and managing a portfolio of differentiated biotherapeutics to improve the standard of care for patients with difficult-to-treat cancers and autoimmune diseases. Leveraging our proprietary antibody engineering platforms, we are advancing a diverse pipeline of multispecific antibodies and antibody-drug conjugates, alongside partnered programs including Ziihera® (zanidatamab-hrii). Our integrated R&D engine and strategic partnerships enable the novel design of next-generation antibody therapeutics addressing significant unmet medical need.
Specialties
- antibody therapeutics
- bispecific antibodies
- ADC
- Breast Cancer
- Gastric Cancer
- protein engineering
- Biliary Tract Cancer
- autoimmune diseases
- inflammatory diseases
- t cell engagers
- and multispecific antibody therapeutics
Company locations
114 E 4th Avenue, Suite 800, Vancouver, BC V5T1G4, CA
Locations listed on the company profile. These may include offices outside Canada, and not every location is hiring.
Business areas
- Life Science
- Biotechnology
- Medical
- Therapeutics
On LinkedIn
- Followers
- 36,975
- People linked to this company
- 268
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Funding raised
1,066,523,699 USD
Total reported by Crunchbase, in US dollars. This is funding raised, not company revenue or valuation.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.